Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation

(2011) Ron Ram et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Relapse of Lymphoma after Allogeneic Hematopoietic Cell Transplantation: Management Strategies and Outcome

(2011) Kitsada Wudhikarn et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

(2010) A. J. Moskowitz et al.   BLOOD

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

(2010) B. Sarina et al.   BLOOD

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

(2009) Marcie Tomblyn et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non-Hodgkin Lymphoma: Importance of Histology for Outcome

(2008) Philippe Armand et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma

(2008) Lauri M. Burroughs et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma

(2008) Ajay K. Gopal et al.   CANCER

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome

(2008) S. P. Robinson et al.   HAEMATOLOGICA

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2007) Anna Sureda et al.   JOURNAL OF CLINICAL ONCOLOGY